An amylin receptor is a calcitonin receptor paired with a RAMP, and in a standard cell line the calcitonin side dominates, so the pharmacology reads as calcitonin, not amylin. Here is why that happens, how a low-expression approach fixes it, and what clean cAMP and β-arrestin readouts across AMY1, AMY2, and AMY3 open up for obesity and diabetes drug discovery.